Literature DB >> 16895663

[Biocompatibility of peritoneal dialysis fluids].

Eric Boulanger1, Olivier Moranne, Marie-Paule Wautier, Jean-Phillipe Rougier, Pierre Ronco, Dominique Pagniez, Jean-Luc Wautier.   

Abstract

Repeated and long-term exposure to conventional glucose-based peritoneal dialysis fluids (PDFs) with poor biocompatibility plays a central role in the pathogenesis of the functional and structural changes of the peritoneal membrane. We have used immortalized human peritoneal mesothelial cells in culture to assess in vitro the biocompatibility of PDFs. Low pH, high glucose concentration and heat sterilization represent major factors of low biocompatibility. Two recent groups of glucose derivatives have been described. Glucose degradation products (GDPs) are formed during heat sterilization (glycoxidation) and storage. GDPs can bind protein and form AGEs (Advanced Glycation End-products), which can also result from the binding of glucose to free NH2 residues of proteins (glycation). The physiological pH, and the separation of glucose during heat sterilization (low GDP content) in the most recent PDFs dramatically increase the biocompatibility. The choice of PD programs with high biocompatibility PDFs allows preserving the function of the peritoneal membrane. Improvement of PDF biocompatibility may limit the occurrence of chronic chemical peritonitis and may allow long-term PD treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16895663     DOI: 10.1016/j.nephro.2005.01.005

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  2 in total

1.  The impact of sub-clinical over-hydration on left ventricular mass in peritoneal dialysis patients.

Authors:  Kamal Hassan; Dunia Hassan; Alexander Shturman; Irina Rubinchik; Hassan Fadi; Hassan Shadi; Shaul Atar
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Does low peritoneal glucose load protect from the development of left ventricular hypertrophy in peritoneal dialysis patients?

Authors:  Kamal Hassan; Fadi Hassan; Dunia Hassan; Saab Anwar; Hassan Shadi
Journal:  Clin Exp Nephrol       Date:  2015-11-22       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.